Immunogenicity of the pentavalent rotavirus vaccine in African infants.

@article{Armah2012ImmunogenicityOT,
  title={Immunogenicity of the pentavalent rotavirus vaccine in African infants.},
  author={George Enyimah Armah and Robert F Breiman and Milagritos D Tapia and Michael J. Dallas and Kathleen M. Neuzil and Fred Newton Binka and Samba Ousmane Sow and Joel Ojwando and Max Ciarlet and A. Duncan Steele},
  journal={Vaccine},
  year={2012},
  volume={30 Suppl 1},
  pages={
          A86-93
        }
}
We recently completed a double-blind, placebo-controlled, multicenter Phase III clinical trial of the pentavalent rotavirus vaccine (PRV) in three African countries, Ghana, Kenya, and Mali, from April 2007 to March 2009. The immunogenicity of PRV in African infants is described. In total, 5468 infants were randomized 1:1 to receive 3 doses of PRV or placebo at approximately 6, 10, and 14 weeks of age. Breastfeeding and concomitant administration of EPI vaccines, including OPV, were allowed, and… 
Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam.
TLDR
Three oral doses of PRV were immunogenic in two GAVI-eligible Asian countries: Bangladesh and Vietnam, and the GMTs of both the serum anti-rotavirus IgA and SNA responses were generally higher in Vietnamese than in Bangladeshi children.
Immunogenicity of pentavalent rotavirus vaccine in Chinese infants.
TLDR
RotaTeqTM was immunogenic in Chinese infants, the seroprotection rates of anti-poliovirus type 1, 2, 3 in the participants who received RV5 were non-inferior to those who received placebo, and the antibody responses to DTaP antigens were comparable between the two vaccination groups.
Efficacy of the oral pentavalent rotavirus vaccine in Mali.
TLDR
The oral, pentavalent rotav virus vaccine (PRV), RotaTeq was assessed for prevention of severe rotavirus gastroenteritis in young children in two multi-site, randomized, placebo-controlled field trials; one in Asia and the other in sub-Saharan Africa.
Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.
TLDR
PRV significantly reduced severe RVGE in Kenya, and the impact of PRV might be greatest in rural Africa in protecting the many children who develop severe gastroenteritis and cannot access health facilities.
A Randomized, Controlled Trial of the Impact of Alternative Dosing Schedules on the Immune Response to Human Rotavirus Vaccine in Rural Ghanaian Infants
TLDR
A third dose of HRV resulted in increased seroconversion frequencies and GMCs, compared with 2 doses administered at 6 and 10 weeks of age, and a postmarketing effectiveness study is required to determine whether the improvement in immune response translates into a public health benefit in low-income countries.
Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial
TLDR
Monovalent human-bovine (116E) rotavirus vaccine is effective and well tolerated in Indian infants, and prevalence of immediate, solicited, and serious adverse events was similar in both groups.
Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants.
TLDR
Overall, the results showed that all three doses of BRV-TV vaccine were safe, well tolerated and displayed good immunogenicity (dose-response) in healthy Indian infants.
A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India
TLDR
Administration of ROTAVAC® at a 0.5 mL dose volume without buffering agent was shown to be well tolerated and immunogenic, and it is plausible that ROT AVAC® replicates well and confers immunity even without buffer administration.
Human Neonatal Rotavirus Vaccine (RV3-BB) Produces Vaccine Take Irrespective of Histo-Blood Group Antigen Status
TLDR
RV3-BB has the potential to provide an improved level of protection in settings where P[6] rotavirus disease is endemic, irrespective of the HBGA profile of the population.
Bovine rotavirus pentavalent vaccine development in India.
TLDR
The bovine rotavirus pentavalent vaccine (BRV-PV) has been found safe and immunogenic and will undergo a large Phase III study to assess efficacy against severe rotav virus gastroenteritis.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
TLDR
PRV appears to be a safe intervention against rotavirus gastroenteritis among infants in Kenya, and SAEs were not significantly more common among HIV-infected or HIV-exposed participants; however, the low number of HIV- infected infants did not provide sufficient power to fully assess safety in HIV- Infected vaccine recipients.
Concomitant Use of the Oral Pentavalent Human-Bovine Reassortant Rotavirus Vaccine and Oral Poliovirus Vaccine
TLDR
Although coadministration with OPV reduced serum antirotavirus IgA geometric mean titer, seroresponse rates were high and consistent with those observed in previous studies showing high vaccine efficacy, and support including PRV in vaccination schedules involving OPV.
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.
TLDR
This vaccine was efficacious in preventing rotavirus gastroenteritis, decreasing severe disease and health care contacts, and the risk of intussusception was similar in vaccine and placebo recipients.
Concomitant Use of an Oral Live Pentavalent Human-Bovine Reassortant Rotavirus Vaccine With Licensed Parenteral Pediatric Vaccines in the United States
TLDR
For the 17 antigens in the concomitantly administered vaccines, antibody responses were similar in PRV and placebo recipients, except for moderately diminished antibody responses to the pertactin component of pertussis vaccine.
Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan.
TLDR
The pentavalent human-bovine vaccine, RotaTeq, was safe, generally well-tolerated, and immunogenic among Taiwanese infants.
Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial
TLDR
In infants in developing countries in Asia, pentavalentrotavirus vaccine is safe and efficacious against severe rotavirus gastroenteritis, and the results support expanded WHO recommendations to promote its global use.
Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines.
TLDR
Evidence is provided that Rix4414 can be co-administered with routine EPI immunizations including OPV and that two doses of RIX4414 were well tolerated and immunogenic in South African infants.
Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
TLDR
Results of a large-scale Phase III clinical study showed that three doses of RotaTeq were immunogenic, efficacious, and well tolerated with no increased clinical risk of intussusception.
Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.
TLDR
Two oral doses of the live attenuated G1P[8] HRV vaccine were highly efficacious in protecting infants against severe rotavirus gastroenteritis, significantly reduced the rate of severe gastroenteropathy from any cause, and were not associated with an increased risk of intussusception.
Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study
TLDR
The results from FES confirm that RV5 induces high and sustained protection against rotavirus-related hospitalisations and ED visits, and has a very substantial impact on all gastroenteritis-relatedospitalisations and emergency department visits into the third year of life in Finnish children.
...
1
2
3
...